The state of the art in biopharmaceutical FUSION PROTEIN DESIGNFusion proteins belong to the most lucrative biotech drugs--with Enbrel(R) being one of the best-selling biologics worldwide. Enbrel(R) represents a milestone of modern therapies just as Humulin(R), the first therapeutic recombinant prot[...]